Abstract：[Abstract]Objective To explore the effect of Recombinant Human Erythropoietin（rhEPO）combined with Iron Sucrose in the treatment of moderate anemia after myomectomy.Methods Fifty-nine patients with uterine fibroids complicated with moderate anemia treated in our hospital from May 2017 to May 2018 were selected as subjects.They were divided into study group（30 cases）and control group（29 cases）by the random number table method.Myomectomy was performed in both groups.The control group was treated with Iron Sucrose，and the study group was treated with rhEPO combined with Iron Sucrose.The clinical efficacy of the two groups was compared，and the hemoglobin（Hb）and mean erythrocyte volume（MCV）levels before operation and on the 5th and 14th day after operation were compared between the two groups.Results Levels of Hb（[92.15±11.30]，[103.47±12.17]g/L）and MCV（[75.23±10.13]，[79.05±10.14]fl）in the study group on the 5th and 14th day after operation were higher than those before operation（[79.1±10.03]g/L，[71.45±10.81]fl），the differences were statistically significant（P＜0.05）.Levels of Hb（[92.01±10.83]，[94.37±11.8]g/L）and MCV（[75.15±10.43]，[75.18±10.21]fl）in the control group on the 5th and 14th day after operation were higher than those before operation（[78.32±11.05]g/L，[71.41±10.96]fl），the differences were statistically significant（P＜0.05）.There were no significant differences in the Hb and MCV between the two groups before operation and on the 5th day after operation（P＞0.05）.The levels of Hb and MCV were higher in observation group than those in control group on the 14th day after operation，the differences were statistically significant（P＜0.05）.The total effective rate（93.33%）in the study group was higher than that in the control group（72.41%），and the difference was statistically significant（P＜0.05）.Conclusion Compared with Iron Sucrose alone，rhEPO combined with Iron Sucrose can relieve moderate anemia after myomectomy.Besides，the curative effects become better over time.
Petruliene K，ZiginskienE E，Kuzminskis V，et al.Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients[J].Medicina（Kaunas），2017，53（2）：90-100.
Delzanno G，Falcone M，Gaudiano L，et al.Human recombinant erythropoietin in the treatment of anemia inobstetricgynecologic patients.Evaluation of such treatment as an alternative to blood transfusion[J].Minerva Ginecol，1996，48（3）：115-118.
[13]
Shepshelovich D，Rozen-Zvi B，Avni T，et al.Intravenous versus oral iron supplementation for the treatment of anemia in CKD：an updated systematic review and Meta-analysis[J].Am J Kidney Dis，2016，68（5）：677-690.
京公网安备 11010502046607号